文献速递乳腺癌

哌柏西利联合帕博利珠单抗及来曲唑治疗激素受体阳性转移性乳腺癌的I/II期试验

Phase I/II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancer.
PubMed 文献 · Eur J Cancer · 2021-07-01

该I/II期试验评估哌柏西利、帕博利珠单抗和来曲唑联合方案在HR+/HER2-转移性乳腺癌患者中的安全性、耐受性和疗效。共入组23例,20例可评估疗效;常见III-IV级不良事件为中性粒细胞减少(83%)。Cohort 2中31%达到完全缓解,中位无进展生存期为25.2个月,中位总生存期为36.9个月。结论认为该联合方案耐受良好,但需确证性试验进一步验证。

要点

  • 联合方案在HR+/HER2-转移性乳腺癌中耐受良好。
  • Cohort 2中完全缓解率为31%,中位PFS为25.2个月。
  • 常见III-IV级不良事件包括中性粒细胞减少(83%)和白细胞减少(65%)。

核心结论

  • 哌柏西利、帕博利珠单抗和来曲唑联合方案在HR+转移性乳腺癌患者中耐受良好,一线治疗中观察到31%的完全缓解率。
  • 需要确证性试验以更好地理解CDK4/6抑制剂的免疫启动效应。

研究设计与样本

  • I/II期试验,入组HR+/HER2- IV期转移性乳腺癌女性患者。
  • Cohort 1中位年龄48岁(33-70),Cohort 2中位年龄55岁(37-75)。
  • Cohort 1因入组有限提前关闭。
  • 主要终点为安全性、耐受性和疗效。

主要发现

  • III-IV级不良事件包括中性粒细胞减少(83%)、白细胞减少(65%)、血小板减少(17%)和肝酶升高(17%)。
  • Cohort 1中50%达到部分缓解(PR),50%为疾病稳定(SD)。
  • Cohort 2中按RECIST 1.1标准,31%达到完全缓解(CR),25%达到PR,31%为SD。
  • Cohort 2中位无进展生存期为25.2个月(95%CI 5.3,未达到),中位总生存期为36.9个月(95%CI 36.9,未达到),中位随访时间为24.8个月(95%CI 17.1,未达到)。

临床怎么用

  • 该联合方案可作为HR+/HER2-转移性乳腺癌患者的一种耐受良好的治疗选择,尤其是一线治疗。
  • 治疗期间需重点监测血液学毒性,尤其是中性粒细胞减少。

局限性

  • 样本量小(共23例),Cohort 1因入组有限提前关闭。
  • 免疫生物标志物分析已另行发表,本报告未包含。
  • 需确证性试验进一步验证疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: CDK4/6 inhibitors modulate immune response in breast cancer. This phase I/II trial was designed to test the safety and efficacy of palbociclib, pembrolizumab and letrozole in women with hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer (MBC). PATIENTS AND METHODS: Women with stage IV HR+ HER2- MBC were enrolled and treated with palbociclib, pembrolizumab and letrozole. Primary end-points were safety, tolerability and efficacy. RESULTS: Between November 2016 and July 2020, 23 patients were enrolled with 20 evaluable for response, including 4 patients in cohort 1 and 16 patients in cohort 2. Cohort 1 median age was 48 years (33-70) and cohort 2 median age was 55 (37-75). Cohort 1 closed early due to limited accrual. Grade III-IV adverse events were neutropenia (83%), leucopaenia (65%), thrombocytopenia (17%) and elevated liver enzymes (17%). In cohort 1, 50% achieved a partial response (PR) and 50% had stable disease (SD). In cohort 2, 31% achieved complete response (CR), 25% had PR and 31% had SD by Response Evaluation Criteria in Solid Tumours version 1.1. Median progression-free survival was 25.2 months (95% confidence interval [CI] 5.3, not reached) and median overall survival was 36.9 months (95% CI 36.9, not reached) in cohort 2 with a median follow-up of 24.8 months (95% CI 17.1, not reached). A correlative immune biomarker analysis was published separately. CONCLUSION: The combination of palbociclib, pembrolizumab and letrozole is well tolerated, and a complete response rate of 31% was identified in HR+ MBC patients who received this combination as front-line therapy. Confirmatory trials are required to better understand the immune-priming effects of CDK4/6 inhibitors.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Yuan Y, Lee JS, Yost SE, et al. Phase I/II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancer. Eur J Cancer. 2021. PMID: 34217908. doi:10.1016/j.ejca.2021.05.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。